Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 632 across all filing types
Latest filing 2020-12-23 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
首次公开发行股票并在科创板上市招股意向书附录
Capital/Financing Update Classification · 95% confidence The document is a detailed issuance sponsorship letter (发行保荐书) for the initial public offering (IPO) and listing on the STAR Market (科创板) of Jiangsu Haoubo Biopharmaceutical Co., Ltd. It includes extensive legal, financial, and compliance information, audit reports, internal control reports, and detailed due diligence findings. The document references audit reports, legal opinions, and internal control verification, all typical components of an IPO prospectus or issuance sponsorship document. It is not a simple announcement or a brief summary but a comprehensive regulatory filing related to the IPO process. This type of document is best classified under Capital/Financing Update (CAP) as it relates to the company's fundraising and capital market activities through the IPO process.
2020-12-23 Chinese
首次公开发行股票并在科创板上市发行安排及初步询价公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the initial public offering (IPO) of Jiangsu Haoyoubo Biopharmaceutical Co., Ltd. on the STAR Market (科创板) of the Shanghai Stock Exchange. It includes extensive information about the issuance arrangement, preliminary inquiry, pricing, investor qualifications, subscription procedures, allotment, lock-up periods, and regulatory approvals. The text references regulatory bodies such as the China Securities Regulatory Commission (CSRC) and Shanghai Stock Exchange, and cites specific regulatory notices and rules related to IPOs on the STAR Market. The document is not a financial report, earnings release, or management discussion, but rather a comprehensive issuance and offering announcement. It is not a brief notice or a report publication announcement but a full detailed document about the IPO issuance process and arrangements. Therefore, the most appropriate classification is Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities such as IPOs.
2020-12-23 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.